Author Interviews, Cost of Health Care, JAMA / 19.05.2020
Access to Pharmaceutical Biosimilars Varies with Insurance Plan
MedicalResearch.com Interview with:
James D. Chambers, PhD, MPharm, MSc
Associate Professor of Medicine
Tufts Medical Center Institute for Clinical Research and Health Policy Studies
MedicalResearch.com: What is the background for this study?
Response: We know that biosimilars have not had the same uptake in the US as they have had elsewhere. We know that this is in part due to reference product manufacturer tactics to delay biosimilar market entry and patent disputes.
In this study we examined whether lack of preferred coverage by commercial health insurers may also play a role.
(more…)
